Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

PTX-022

Small molecule · Inhibitor of mechanistic target of rapamycin (mTOR) (MTOR) · developed by Palvella Therapeutics

Phase 3 Most advanced trial
PVLA Developer
1 Registered trials

What is PTX-022?

PTX-022 is a topical gel containing sirolimus (rapamycin). After application, sirolimus enters basal keratinocytes and forms a complex with FKBP-12 that inhibits mTOR and mTOR-mediated signaling, reducing proliferation. It is studied in pachyonychia congenita.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
mechanistic target of rapamycin (mTOR) (MTOR), FK binding protein-12 (FKBP-12) (FKBP1A) (binding partner it blocks)
Mechanism
Inhibitor of mechanistic target of rapamycin (mTOR) (MTOR)
Pathways
mTOR signaling, keratin mRNA translation, keratinocyte proliferation
Therapy area
Dermatology
Developer
Palvella Therapeutics, Inc. (PVLA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05643872 Phase 3 Pachyonychia Congenita Recruiting PVLA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Pachyonychia Congenita

Other drugs acting on MTOR

More from Palvella Therapeutics

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PVLA page.

Follow PVLA, the company behind PTX-022

See PVLA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PVLA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.